The regulatory reforms and government-industry co-operation have improved the global competitiveness of Japan’s pharmaceutical industry, which is the world’s second largest.

Japan is a major technologically-sophisticated healthcare market, with a rapidly ageing population. The country has a strong research base, with particular strengths in the application of electronics to medical and social needs.

The Japanese pharmaceutical industry has evolved dramatically over the past decade and is continuing to adapt to the evolving demands of the international healthcare markets. Given the massive development costs that it faces, the pharmaceutical industry in Japan is undergoing major changes. As a result the business environment in which pharmaceutical companies find themselves is transforming rapidly.

 Interphex Japan , world's leading and firmly established B-to-B trade show specialised in pharmaceuticals will be held at Tokyo International Exhibition Center (Tokyo Big Sight) at a time the pharma industry in Japan is undergoing major transformation

With the concurrently held in-Pharma Japan, the show covers the whole process of pharmaceutical production and serves as the best business platform to understand the latest, innovative products and technologies from Japan, Asia and the rest of the world.

It is the world's leading pharmaceutical event, covering the whole process of pharmaceutical R&D and manufacturing, from all kinds of equipment to lab devices, contract services, packaging, total solutions and so on. Firmly established as an annual event for industry professionals to gather at one place for business, the show has been expanding its scale every year.

Interphex Japan will witness participation of manufacturers and dealers of pharmaceutical industry. Approximately 1,750 exhibitors will be coming to this event from different parts of the globe to demonstrate their latest products and services. Dealers linked to R&D to manufacturing, packaging, contract services will also be participating in this event as exhibitors.

The event will be ideal for people who are seeking the latest information pertaining to pharmaceutical industry. The professionals of pharmaceutical industry linked to manufacturing technology, R&D, product quality control, factory control, purchasing/facilities, information technology and lots more will be visiting this event.

Interphex Japan will be beneficial for all the participants as they will be able to see actual products and technologies, meet face-to-face with potential partners, find solutions to needs and requirements and many more. The manufacturers of this industry will be demonstrating their latest products and services before the target audiences.

In the meanwhile in-Pharma Japan, Asia's leading B-to-B ingredients trade show , will prove to be the ultimate venue for pharmaceutical manufactures to meet, discuss and expand the connections with ingredients suppliers from Japan and Asia.

in-Pharma Japan, Asia's leading ingredients trade show, is the best way to penetrate Japanese market, the second largest pharma market in the world, according to Megumi Yanai, sales director, Reed Exhibitions Japan Ltd.

Speaking at a road show on seventh in-Pharma Japan organised by Reed Exhibitions and supported by IDMA, she said that the event will be attracting over 150 exhibitors worldwide and 35,000 professionals in the industry.

The exhibit profile includes pharmaceutical ingredients, APIs, intermediates, additives, functional ingredients, natural extracts, fine chemicals, outsourcing, OEM various analytical services and equipment and other ingredients. At the same time the visitor profile includes decision makers and executives from pharmaceutical manufacturers, R&D, purchasing, production, quality control management, engineering, marketing and sales and all other related divisions and departments.

The organisers provide a unique search engine by which a visitor can contact an estimated 3,000 professionals in advance, find target customers, make appointments before the show, learn potential customers needs before hand and make proposals on-site.

Special support services for exhibitors include direct mailing, exclusive VIP Customer Registration System, VIP networking reception party, e-Guidebook & Web Link Service, press release service, presentation at exhibitors' product/ technology seminar and other support services.

Through direct mailing thousands of invitation tickets will be sent out to industry executives and professionals in Japan and all over the world. These invitation tickets will include the participant company name, which enhance the company to gain further recognition among industry professionals.

Exclusive VIP Customer Registration System helps the exhibitor strengthen connection with the most valued customers. The company can invite top executives in customers list as "VIP guests" so that they can take advantage of the privileges.

VIP Networking Reception Party is a unique opportunity to establish network and exchange information among industry executives, such as CEOs, CTOs, presidents, vice presidents, directors, professionals etc.

in-Pharma Japan is the best business platform for pharmaceutical ingredients suppliers to expand sales and network in the Japanese pharmaceutical industry.

According to some of the industry experts, Japan is a market that cannot be ignored by Indian pharma companies. The switch to generic drugs has created a demand not just for active pharmaceutical ingredients but also formulations.

 Presently, India is targeting the Japanese generics market vigorously. Aided by a free trade agreement with Japan, which makes it easier to form business alliances with local firms, Indian bulk drug makers are looking to give a stronger focus on the Japanese market. Furthermore, India’s growing respect and legal/regulatory framework are making the country able to maintain a large basket of high quality affordable generics with assured safety and efficacy.

The top 25 Indian companies are looking at a strategic entry into Japan through acquisition, collaboration or entry through distributors. Companies present in the region are Daiichi-Ranbaxy, Lupin, Glenmark, Zydus. These companies including Micro Labs, Bal Pharma and Biocon from Karnataka are keen to leverage the advantage of an early entry into Japan. Rising healthcare costs, ageing population and high cost of drug development in Japan will offer Indian generic majors a great opportunity, said officials from the Japan External Trade Organization (JETRO).